University of Turin-ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2024

  1. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

    Nature, Vol. 629, Núm. 8013, pp. 919-926

  2. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma

    Cell Reports Medicine, Vol. 5, Núm. 8

  3. Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node

    Molecular Oncology, Vol. 18, Núm. 6, pp. 1355-1377

  4. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

    Nature Communications, Vol. 15, Núm. 1

  5. Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 121, Núm. 36

2022

  1. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 28, Núm. 8, pp. 1640-1650

  2. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)

    Cancer Treatment Reviews, Vol. 103

2021

  1. Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer

    Trends in Cancer, Vol. 7, Núm. 5, pp. 410-429

2020

  1. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma

    JCI Insight, Vol. 5, Núm. 15

2018

  1. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

    Cell, Vol. 172, Núm. 4, pp. 857-868.e15

2014

  1. Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts

    Cancer Research, Vol. 74, Núm. 21, pp. 5978-5988